Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01108562|
Recruitment Status : Withdrawn
First Posted : April 22, 2010
Last Update Posted : April 6, 2015
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Pain Management After Total Hip Arthroplasty||Drug: Lidocaine Other: Normal Saline||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia: a Prospective Randomized, Double-blinded, Placebo-controlled Study|
|Study Start Date :||February 2008|
|Estimated Primary Completion Date :||August 2008|
Placebo Comparator: Control Group
Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
Other: Normal Saline
Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
Experimental: Lidocaine Group
Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
- We propose to test the hypothesis that adding a low dose lidocaine infusion to patient controlled analgesia will lower the amount of opioids that these patients will receive, thereby improving patient safety while still providing adequate analgesia. [ Time Frame: 24 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01108562
|Principal Investigator:||Michelle L Schlunt, MD||Loma Linda University Medical Center|